HCV and Diabetes Mellitus: Considerations About Effects of Interferon Therapy

L. Reynaud, M. A. Carleo, M. Talamo, G. Borgia
{"title":"HCV and Diabetes Mellitus: Considerations About Effects of Interferon Therapy","authors":"L. Reynaud, M. A. Carleo, M. Talamo, G. Borgia","doi":"10.2174/1874143600701010027","DOIUrl":null,"url":null,"abstract":"Nowadays HCV-related chronic hepatitis represents one of the main challenge for infectious diseases for many reasons: the dimension of the phenomenon, as millions of patients are afflicted with this pathology in the world, the dra- matic consequences on the quality of their life, the economic and sanitary efforts sustained by the society, but also the stimulating results in therapeutic approach due to the introduction of interferons in monotherapy first and association ther- apy (IFN plus ribavirin) later in modern protocols. The results obtained with these therapies are very encouraging even if medical doctors and patients know very well that this therapy is related to some side effects that grow dramatically in number with the progression of scientific knowledge. The Authors review the literature on the relationship among HCV, IFN therapy and diabetes to understand better damages and benefits of this long debated matter and possibly add their contribution to clinical and therapeutic strategies.","PeriodicalId":22907,"journal":{"name":"The Open Pharmacology Journal","volume":"17 1","pages":"27-29"},"PeriodicalIF":0.0000,"publicationDate":"2007-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Open Pharmacology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874143600701010027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Nowadays HCV-related chronic hepatitis represents one of the main challenge for infectious diseases for many reasons: the dimension of the phenomenon, as millions of patients are afflicted with this pathology in the world, the dra- matic consequences on the quality of their life, the economic and sanitary efforts sustained by the society, but also the stimulating results in therapeutic approach due to the introduction of interferons in monotherapy first and association ther- apy (IFN plus ribavirin) later in modern protocols. The results obtained with these therapies are very encouraging even if medical doctors and patients know very well that this therapy is related to some side effects that grow dramatically in number with the progression of scientific knowledge. The Authors review the literature on the relationship among HCV, IFN therapy and diabetes to understand better damages and benefits of this long debated matter and possibly add their contribution to clinical and therapeutic strategies.
丙型肝炎与糖尿病:干扰素治疗效果的考虑
目前,丙型肝炎相关慢性肝炎是传染病的主要挑战之一,原因有很多:这一现象的规模,由于世界上数百万患者受到这种病理的折磨,对他们的生活质量的戏剧性后果,社会持续的经济和卫生努力,以及由于首先在单药治疗中引入干扰素和后来在现代方案中引入联合治疗(干扰素加利巴韦林)而在治疗方法上产生的刺激结果。尽管医生和病人都很清楚,这种疗法会带来一些副作用,而且随着科学知识的进步,这些副作用会急剧增加,但这些疗法取得的结果还是非常令人鼓舞的。作者回顾了关于丙型肝炎病毒、干扰素治疗和糖尿病之间关系的文献,以更好地了解这一长期争论的问题的危害和益处,并可能增加他们对临床和治疗策略的贡献。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信